Three Seasons Wealth LLC Invests $1.30 Million in Thermo Fisher Scientific Inc. (NYSE:TMO)

Three Seasons Wealth LLC purchased a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 2,501 shares of the medical research company's stock, valued at approximately $1,302,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Stonegate Investment Group LLC increased its stake in shares of Thermo Fisher Scientific by 0.3% in the fourth quarter. Stonegate Investment Group LLC now owns 6,788 shares of the medical research company's stock worth $3,531,000 after purchasing an additional 18 shares during the period. Semus Wealth Partners LLC increased its stake in shares of Thermo Fisher Scientific by 4.0% in the fourth quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company's stock worth $245,000 after purchasing an additional 18 shares during the period. Bangor Savings Bank increased its stake in shares of Thermo Fisher Scientific by 6.0% in the fourth quarter. Bangor Savings Bank now owns 334 shares of the medical research company's stock worth $174,000 after purchasing an additional 19 shares during the period. Eagle Rock Investment Company LLC increased its stake in shares of Thermo Fisher Scientific by 0.3% in the fourth quarter. Eagle Rock Investment Company LLC now owns 7,463 shares of the medical research company's stock worth $3,882,000 after purchasing an additional 19 shares during the period. Finally, KRS Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 1.5% in the fourth quarter. KRS Capital Management LLC now owns 1,317 shares of the medical research company's stock worth $685,000 after purchasing an additional 20 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

Shares of TMO traded down $2.69 on Monday, hitting $421.55. The company's stock had a trading volume of 2,527,222 shares, compared to its average volume of 1,746,685. The company has a market capitalization of $159.13 billion, a PE ratio of 25.50, a PEG ratio of 2.99 and a beta of 0.86. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a fifty-two week low of $409.85 and a fifty-two week high of $627.88. The company has a 50 day moving average price of $487.28 and a 200 day moving average price of $526.70.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. The business had revenue of $10.36 billion for the quarter, compared to the consensus estimate of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. Thermo Fisher Scientific's revenue was up .2% compared to the same quarter last year. During the same period in the previous year, the business earned $5.11 EPS. On average, research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, April 15th. Investors of record on Friday, March 14th were issued a $0.43 dividend. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Friday, March 14th. This represents a $1.72 annualized dividend and a yield of 0.41%. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.09%.

Analyst Ratings Changes

A number of research firms have recently commented on TMO. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a "market perform" rating to an "outperform" rating and set a $630.00 price objective on the stock in a research note on Friday, January 10th. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday. UBS Group lowered their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a "buy" rating on the stock in a research note on Thursday. The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the company a "buy" rating in a research note on Wednesday. Finally, Royal Bank of Canada lowered their price target on Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday. Five equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $616.95.

Insider Buying and Selling

In related news, CFO Stephen Williamson sold 9,825 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the completion of the sale, the chief financial officer now directly owns 27,296 shares in the company, valued at $15,984,264.64. This trade represents a 26.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the completion of the sale, the executive vice president now owns 16,363 shares of the company's stock, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock worth $13,106,062 over the last three months. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.